局部晚期胰腺癌的剂量递增:我们能提高到多高?
本研究对20例曾在本院接受SBRT或剂量递增超分割IMRT的局部晚期不可切除胰腺癌患者,按GTV 70 Gy/5次、PTV 40 Gy/5次重新计划。结果显示GTV 60 Gy覆盖率达61.3%,60 Gy剂量递增在剂量学上可行且满足正常组织约束,相关OAR约束将用于正在进行的临床试验。
要点
- GTV 50 Gy覆盖率为91%,60 Gy为61.3%,70 Gy为24.4%。
- PTV 70 Gy最大覆盖率为33%,PTV 60 Gy最大覆盖率为77.5%。
- 60 Gy剂量递增在剂量学上可行,GTV覆盖充分。
核心结论
- 剂量递增至60 Gy在剂量学上可行,且GTV覆盖充分。
- 确定的OAR约束将用于正在进行的临床试验。
研究设计与样本
- 剂量学研究,对20例在本院接受SBRT或剂量递增超分割IMRT(DE-IMRT)的局部晚期不可切除胰腺癌患者进行重新计划。
- 重新计划采用剂量递增SBRT,GTV给予70 Gy/5次,PTV给予40 Gy/5次,计划使用标准公认的危及器官(OAR)约束。
主要发现
- iGTV 50 Gy平均覆盖率为91%(±0.07%),60 Gy为61.3%(±0.08%),70 Gy为24.4%(±0.05%)。
- PTV 70 Gy最大覆盖率为33%,PTV 60 Gy最大覆盖率为77.5%。
- 90%的计划达到以下OAR约束:十二指肠V20<30 cc、V30<3 cc、V35<1 cc;小肠V20<15 cc、V30<1 cc、V35<0.1 cc;胃V20<20 cc、V30<2 cc、V35<1 cc。
- 所有OAR均达到V40<0.5 cc。
关键数值与推荐
- 十二指肠约束:V20<30 cc、V30<3 cc、V35<1 cc(90%计划达到)。
- 小肠约束:V20<15 cc、V30<1 cc、V35<0.1 cc(90%计划达到)。
- 胃约束:V20<20 cc、V30<2 cc、V35<1 cc(90%计划达到)。
- 所有OAR约束:V40<0.5 cc(全部计划达到)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are limited treatment options for locally advanced, unresectable pancreatic cancer (LAPC) and no likelihood of cure without surgery. Radiation offers an option for local control, but radiation dose has previously been limited by nearby bowel toxicity. Advances in on-board imaging and treatment planning may allow for dose escalation not previously feasible and improve local control. In preparation for development of clinical trials of dose escalation in LAPC, we undertook a dosimetric study to determine the maximum possible dose escalation while maintaining known normal tissue constraints. METHODS AND MATERIALS: Twenty patients treated at our institution with either SBRT or dose-escalated hypofractionated IMRT (DE-IMRT) were re-planned using dose escalated SBRT to 70 Gy in 5 fractions to the GTV and 40 Gy in 5 fractions to the PTV. Standard accepted organ at risk (OAR) constraints were used for planning. Descriptive statistics were generated for homogeneity, conformality, OAR's and GTV/PTV. RESULTS: Mean iGTV coverage by 50 Gy was 91% (±0.07%), by 60 Gy was 61.3% (±0.08%) and by 70 Gy was 24.4% (±0.05%). Maximum PTV coverage by 70 Gy was 33%. Maximum PTV coverage by 60 Gy was 77.5%. The following organ at risk (OAR) constraints were achieved for 90% of generated plans: Duodenum V20 < 30 cc, V30 < 3 cc, V35 < 1 cc; Small Bowel V20 < 15 cc, V30 < 1 cc, V35 < 0.1 cc; Stomach V20 < 20 cc, V30 < 2 cc, V35 < 1 cc. V40 < 0.5 cc was achieved for all OAR. CONCLUSIONS: Dose escalation to 60 Gy is dosimetrically feasible with adequate GTV coverage. The identified constraints for OAR's will be used in ongoing clinical trials.
引用
- Colbert LE, Rebueno N, Moningi S, et al. Dose escalation for locally advanced pancreatic cancer: How high can we go? Adv Radiat Oncol. 2018. PMID: 30370371. doi:10.1016/j.adro.2018.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。